Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 2 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 2.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Dr. Trevor L. Hawkins is an independent director and Chair of the Audit Committee of Blue Water Acquisition Corp. IV (NYSE: BWIV.U), a special purpose acquisition company that completed its IPO in March 2026. He was appointed to the BWIV board on March 19, 2026, alongside Timothy N. Coulson and Laurent D. Hermouet, as part of the SPAC's formation. Prior to joining the Blue Water Acquisition Corp. IV board, Hawkins also served as a director of Blue Water Acquisition Corp. III, from which he resigned effective upon the closing of that vehicle's transactions. During his tenure at BWIV, the SPAC entered into a non-binding letter of intent with Maha Capital AB (publ) in April 2026 for a reverse merger transaction, though that proposed deal was subsequently cancelled in May 2026. The SPAC trades on the NYSE with an approximate market capitalization of $181 million.
Hawkins has built a recognized career spanning more than 30 years in the healthcare industry, encompassing business leadership, academic innovation, and entrepreneurship. He previously served as Director of the U.S. Department of Energy's Human Genome Project, a landmark scientific initiative. He is currently the CEO of HP Health and serves as an advisor to GreyBird Ventures. Hawkins has published over 50 peer-reviewed articles on automation, genomics, human diseases, and the Human Genome Project, and he invented and patented the use of magnetic beads for nucleic acids purification. He is also currently writing a book on the impact of COVID-19 on global healthcare networks. His areas of deep expertise include diagnostics, in vitro diagnostics, genomics, point-of-care testing, molecular diagnostics, FDA regulatory strategy, and life sciences strategy.
As an active investor and board member, Hawkins has approximately 10 years of investing experience with six portfolio investments, most recently in December 2023. He currently holds board seats at several international healthcare and diagnostics companies, including Resistell (a Swiss medical device company developing rapid antibiotic susceptibility testing, joined December 2023), lifespin GmbH (a German deep-data company building an AI-based metabolomics health-testing platform, joined October 2021), GNA Biosolutions GmbH (a German molecular diagnostics company with proprietary Pulse Controlled Amplification technology, joined November 2019), and Noscendo GmbH (a Duisburg-based molecular diagnostics company focused on identifying infection-causing microbes via next-generation sequencing, joined November 2019). He also serves on the board of Youth Music Monterey County, a nonprofit youth orchestra organization, since January 2023. Hawkins is based in the San Francisco Bay Area, United States.
This record is keyed to SEC CIK 0002070377 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 4 institutional-holder rows on these vehicles, under 4 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.